In this trial, we are evaluating the safety, tolerability, and blood concentration of new medication to treat fibrotic diseases of the liver, lung and skin. A fibrotic disease is an illness where tough, scar-like tissue forms in body organs where it doesn’t belong, and causes a loss of normal function in those organs. This new medication may potentially inhibit (or decrease the effect of) a chemical called autotaxin that is made by the human body, and is thought to be involved in fibrotic diseases.
For this trial we need the help of healthy males and females with no history of any medical conditions, aged 18-55 years, weighing between 45-110kgs and have a BMI between 18-32kgm².
Eligible participants will be reimbursed for their time. If you meet the criteria for this study and would like more information, register below or call 1800 727 874.